A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs RG 6100 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 13 Nov 2017 According to an AC Immune media releaseAC Immune became eligible to receive a milestone payment of CHF 14 million upon the dosing of the first patient of this trial.
- 07 Nov 2017 According to an AC Immune media release, the first patient has been dosed in this trial.
- 31 Oct 2017 Planned End Date changed from 30 Nov 2022 to 20 Sep 2022.